Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Arq. neuropsiquiatr ; 77(2): 73-79, Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-983882

ABSTRACT

ABSTRACT Mutations of the GBA gene have been reported in patients with Parkinson's disease (PD) from a number of different countries, including Brazil. In order to confirm this pattern in a sample of PD patients from northern Brazil, we conducted a case-control study of the occurrence of the two most common mutations of the GBA gene (c.1226A>G; p.N370S and c.1448T>C; p.L444P) in a group of 81 PD patients and 81 control individuals, using PCR-RFLP, confirmed by the direct sequencing of the PCR products. In the patient group, three patients (3.7%) were heterozygous for the GBA c.1226A>G; p.N370S mutation, and three (3.7%) for GBA c.1448T>C; p.L444P Neither mutation was detected in the control group (p =0.0284). Patients with the c.1448T>C; p.L444P mutation showed a tendency to have an earlier disease onset, but a larger sample number is required to confirm this observation. Our results suggest an association between the GBA c.1226A>G; p.N370S and c.1448T>C; p.L444P mutations and the development of PD in the population of patients from the Northern Brazil.


RESUMO Mutações no gene GBA têm sido reportadas em pacientes com doença de Parkinson (DP) em diferentes países, incluindo o Brasil. Com o objetivo de confirmar esse padrão em uma amostra de pacientes com DP provenientes do Norte brasileiro, foi conduzindo esse estudo caso-controle investigando a frequência das duas mutações mais comuns do gene GBA (c.1226A>G; p.N370S e c.1448T>C; p.L444P) em um grupo de 81 pacientes com DP e 81 controles, usando PCR-RFLP e confirmado pelo sequenciamento direto de produtos de PCR. No grupo experimental, três pacientes (3,7%) foram heterozigotos para a mutação c.1226A>G; p.N370S e três (3,7%), para a mutação c.1448T>C; p.L444P Nenhuma das duas mutações foi detectada no grupo controle (p =0,0284). Pacientes com a mutação c.1448T>C; p.L444P demonstraram uma tendência a apresentar os sintomas mais precocemente, porém um número amostrai maior é necessário para confirmar essa observação. Nossos resultados sugerem uma associação entre essas duas mutações no gene GBA e o desenvolvimento de DP na população de pacientes do norte Brasileiro.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Parkinson Disease/genetics , Glucosylceramidase/genetics , Mutation/genetics , Polymorphism, Restriction Fragment Length , Brazil , Case-Control Studies , Polymerase Chain Reaction , Cross-Sectional Studies , Risk Factors , Age of Onset , Genetic Association Studies
4.
Experimental & Molecular Medicine ; : e153-2015.
Article in English | WPRIM | ID: wpr-57313

ABSTRACT

Lysosomal dysfunction is a common pathological feature of neurodegenerative diseases. GTP-binding protein type A1 (GBA1) encodes beta-glucocerebrosidase 1 (GCase 1), a lysosomal hydrolase. Homozygous mutations in GBA1 cause Gaucher disease, the most common lysosomal storage disease, while heterozygous mutations are strong risk factors for Parkinson's disease. However, whether loss of GCase 1 activity is sufficient for lysosomal dysfunction has not been clearly determined. Here, we generated human neuroblastoma cell lines with nonsense mutations in the GBA1 gene using zinc-finger nucleases. Depending on the site of mutation, GCase 1 activity was lost or maintained. The cell line with GCase 1 deficiency showed indications of lysosomal dysfunction, such as accumulation of lysosomal substrates, reduced dextran degradation and accumulation of enlarged vacuolar structures. In contrast, the cell line with C-terminal truncation of GCase 1 but with intact GCase 1 activity showed normal lysosomal function. When alpha-synuclein was overexpressed, accumulation and secretion of insoluble aggregates increased in cells with GCase 1 deficiency but did not change in mutant cells with normal GCase 1 activity. These results demonstrate that loss of GCase 1 activity is sufficient to cause lysosomal dysfunction and accumulation of alpha-synuclein aggregates.


Subject(s)
Humans , Cell Line , Enzyme Activation/genetics , Gene Knockout Techniques , Gene Order , Genetic Loci , Glucosylceramidase/genetics , Lysosomes/metabolism , Mutation , Protein Aggregation, Pathological/genetics , Protein Binding , Zinc Fingers , alpha-Synuclein/chemistry
6.
Biomédica (Bogotá) ; 26(3): 434-435, sept. 2006. tab
Article in Spanish | LILACS | ID: lil-475411

ABSTRACT

Introducción. La enfermedad de Gaucher es una condición panétnica, caracterizada por la acumulación de glucosilceramida en los macrófagos. La causa principal de esta enfermedad en algunos países occidentales, incluido Colombia, es la mutación N370S, en el gen de la glucocerebrosidasa localizado en 1q21. Objetivo. Determinar el grado de asociación entre la mutación N370S y los alelos de cinco microsatélites cercanos al sitio de la mutación en nueve pacientes colombianos Gaucher tipo 1, procedentes del altiplano cundiboyacense. Materiales y métodos. A partir del ADN de los pacientes, sus familiares cercanos y 30 individuos control, los loci: D1S305, D1S2624, D1S2777, ITG6.6.2 y 5GC3.2 fueron amplificados mediante reacción en cadena de la polimerasa. Las frecuencias alélicas por microsatélite fueron calculadas en pacientes y controles y 11 haplotipos N370S fueron inferidos y se determinó el grado de desequilibrio de ligamiento entre los alelos de cada haplotipo con la mutación N370S. Resultados. Se encontró un haplotipo consenso N370S compuesto por los alelos 222-314- 260-301-172 (pares de bases) que corresponden a los microsatélites: 5GC3.2 ITG6.6.2, D1S2777 D1S2624 y D1S305 respectivamente. Hubo desequilibrio de ligamiento significativo entre los alelos de 222, 314, 260 y 301 pares de bases y la mutación N370S. Conclusión. Una fracción conservada del haplotipo pudo haber estado asociada la mutación en un cromosoma ancestral al grupo de pacientes, cuya procedencia étnica es aún desconocida.


Introduction. Gaucher disease is a pan-ethnic condition characterised by glucosylceramide accumulation in macrophages due to glucocerebrosidase deficiency. Its gene, GBA, has been mapped to 1q21 and mutation N370S is the main cause of the disease in western populations, including Colombia. Objective. To asses the degree of association between N370S mutation and the alleles of five microsatellites near the mutation site in the GBA locus in nine Colombian Gaucher patients, from the Cundinamarca-Boyacá region. Materials and methods. DNA from patients bearing the N370S mutation, their closest relatives, and 30 controls was taken to PCR-amplify the markers: D1S305, D1S2624, D1S2777, ITG6.6.2 and 5GC3.2. Allele frequencies were calculated, haplotypes inferred and linkage disequilibrium levels between marker alleles and N370S were also estimated Results. Eleven N370S chromosomes were obtained. A consensus N370S haplotype consisting of the alleles: 222-314-260-301-172 (base pairs) was identified. Each allele corresponding to markers 5GC3.2, ITG6.6.2, D1S277, D1S2624 and D1S305, respectively. There was statistically significant linkage disequilibrium between the alleles of 222, 314, 260, 301 base pairs and the N370S mutation.Conclusion. A conserved fraction of the haplotypes suggests that N370S may be present among patients and stem from a single ancestral chromosome for which the ethnic origin is still unclear.


Subject(s)
Gaucher Disease/genetics , Glucosylceramidase/genetics , Haplotypes , Mutation , Polymerase Chain Reaction
7.
Journal of Korean Medical Science ; : 733-738, 2006.
Article in English | WPRIM | ID: wpr-211998

ABSTRACT

Gaucher disease is caused by a deficiency of glucocerebrosidase. Patients with Gaucher disease are divided into three major phenotypes: chronic nonneuronopathic, acute neuronopathic, and chronic neuronopathic, based on symptoms of the nervous system, the severity of symptoms, and the age of disease onset. The characteristics of patients with acute neuronopathic- and chronic neuronopathic-type Gaucher disease include oculomotor abnormalities, bulbar signs, limb rigidity, seizures and occasional choreoathetoid movements, and neuronal loss. However, the mechanisms leading to the neurodegeneration of this disorder remain unknown. To investigate brain dysfunction in Gaucher disease, we studied the possible role of inflammation in neurodegeneration during development of Gaucher disease in a mouse model. Elevated levels of the proinflammatory cytokines, IL-1alpha, IL-1beta, IL-6, and TNF-alpha, were detected in the fetal brains of Gaucher mice. Moreover, the levels of secreted nitric oxide and reactive oxygen species in the brains of Gaucher mice were higher than in wild-type mice. Thus, accumulated glucocerebroside or glucosylsphingosine, caused by glucocerebrosidase deficiency, may mediate brain inflammation in the Gaucher mouse via the elevation of proinflammatory cytokines, nitric oxide, and reactive oxygen species.


Subject(s)
Mice , Animals , Up-Regulation/genetics , Tumor Necrosis Factor-alpha/genetics , Reverse Transcriptase Polymerase Chain Reaction , Reactive Oxygen Species/metabolism , RNA, Messenger/genetics , Nitric Oxide/metabolism , Microglia/cytology , Mice, Knockout , Mice, Inbred ICR , Mice, Inbred C57BL , Interleukin-6/genetics , Interleukin-1/genetics , Inflammation/immunology , Glucosylceramidase/genetics , Gaucher Disease/genetics , Cytokines/genetics , Cells, Cultured , Brain/embryology
8.
Genet. mol. res. (Online) ; 4(3): 491-495, 2005. ilus
Article in English | LILACS | ID: lil-444963

ABSTRACT

Gaucher disease, the most common lysosomal storage disorder, is currently treated with enzyme replacement therapy. This approach, however, is ineffective in altering the progression of neurodegeneration in type 2 and type 3 patients due to the difficulty of transferring the recombinant enzyme across the blood-brain barrier. Human immunodeficiency virus type 1 trans-activating transcriptional activator protein (HIV TAT) contains a protein transduction domain that can be added to a fusion protein partner to allow for transport of the partner across membranes. Consequently, we examined the creation, production, and secretion of fusion constructs containing glucocerebrosidase and either wild-type TAT or modified TAT in Sf9 cells. All three constructs exhibited successful expression, with wild-type TAT chimeras showing lower levels of expression than modified TAT chimeras.


Subject(s)
Humans , Glucosylceramidase/biosynthesis , Gene Products, tat/metabolism , Cells, Cultured , Gaucher Disease/metabolism , Gaucher Disease/therapy , Glucosylceramidase/genetics , Cell Line , Cell Membrane/metabolism , Gene Products, tat/genetics , Transcription, Genetic , Transduction, Genetic , Protein Transport/genetics
SELECTION OF CITATIONS
SEARCH DETAIL